Medicine and Dentistry
Development
100%
Epigenomics
100%
Malignant Neoplasm
100%
Epigenetic Modification
100%
Ligand
42%
Neoplasm
28%
Gene
28%
Upregulation
28%
Tumor Microenvironment
28%
T Cell
28%
Immunoglobulin
28%
Immunosurveillance
28%
Clinical Trial
14%
Protein
14%
DNA Methylation
14%
Methylation
14%
Disease
14%
Tumor Cell
14%
Promoter Region
14%
Acetylation
14%
Host
14%
Mucin
14%
Histone Deacetylase Inhibitor
14%
Cytotoxic T-Cell
14%
Cancer Treatment
14%
Transcriptomics
14%
Therapeutic Modality
14%
Lymphocyte Activation
14%
Programmed Death 1 Receptor
14%
Immunomodulating Agent
14%
Pharmacology, Toxicology and Pharmaceutical Science
Ligand
100%
Malignant Neoplasm
100%
Neoplasm
100%
Tumor Microenvironment
66%
Immunoglobulin
66%
Clinical Trial
33%
Diseases
33%
Protein
33%
Programmed Death 1 Receptor
33%
DNA
33%
Immunomodulating Agent
33%
Host
33%
Histone
33%
Mucin
33%
DNA Methyltransferase
33%
Histone Deacetylase Inhibitor
33%
Immunology and Microbiology
Epigenetic Modification
100%
Epigenetics
100%
Development
100%
Gene
28%
T Cell
28%
Upregulation
28%
Intravenous Immunoglobulin
28%
Immunosurveillance
28%
Mucin
14%
Cytotoxic T Cell
14%
Host
14%
Methylation
14%
Promoter Region
14%
Transcriptomics
14%
Tumor Cell
14%
Acetylation
14%
DNA Methylation
14%
Programmed Death 1 Receptor
14%
Lymphocyte Activation
14%
Histone Modification
14%
Immunomodulating Drugs
14%